Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.8805
-0.0208 (-2.31%)
Nov 18, 2026, 12:57 PM EST - Market open
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $41.56M in the twelve months ending September 30, 2026, up 2.48% year-over-year. In the year 2025, Spero Therapeutics had annual revenue of $66.80M with 39.24% growth. That makes Spero Therapeutics the 29,314th largest company in the world by revenue and 3,895th in the United States.
Revenue (ttm)
$41.56M
Revenue Growth
+2.48%
P/S Ratio
1.26
Revenue / Employee
$1,662,200
Employees
25
Market Cap
51.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.80M | 18.83M | 39.24% |
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
| Dec 31, 2019 | 18.15M | 14.18M | 357.56% |
| Dec 31, 2018 | 3.97M | 1.99M | 100.40% |
| Dec 31, 2017 | 1.98M | 1.64M | 490.75% |
| Dec 31, 2016 | 335.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 148.22M |
| Xilio Therapeutics | 55.01M |
| Verrica Pharmaceuticals | 22.89M |
| Werewolf Therapeutics | 21.00M |
| RenovoRx | 2.78M |
| Impact BioMedical | 38.00K |
SPRO News
- 5 days ago - Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Spero Therapeutics Quarterly report: Q3 2026 - Filings
- 6 days ago - Spero Therapeutics Earnings release: Q3 2026 - Filings
- 8 days ago - Spero Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 8 days ago - Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors - GlobeNewsWire
- 13 days ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Spero Therapeutics to Present at Investor Conferences in November - GlobeNewsWire
- 21 days ago - Spero Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly